Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - idiopaatiline, trombotsütopeeniline purpur - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - atezolüsumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastilised ained - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Eesti - eesti - Ravimiamet

zoetis belgium - linkomütsiin+spektinomütsiin - pulber joogivees manustamiseks - 222mg+444,7mg 1g 150g 1tk; 222mg+444,7mg 1g 1500g 1tk

Eesti - eesti - Ravimiamet

intervet international b.v. - koktsiidide vaktsiin - suukaudse suspensiooni suspensioon - 1annus 0.004ml 20ml 5tk

Eesti - eesti - Ravimiamet

intervet international b.v. - koktsiidide vaktsiin - suukaudse suspensiooni suspensioon - 1annus 0.004ml 20ml 1tk; 1annus 0.1ml 100ml 1tk; 1annus 0.1ml 500ml 1tk; 1annus 0.004ml 4ml 1tk; 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

ceva-phylaxia zrt. - lindude rinotrahheiidi viirusvaktsiin - okulonasaalsuspensiooni lüofilisaat - 1annus 500annus 20tk; 1annus 5000annus 1tk; 1annus 2500annus 1tk; 1annus 500annus 10tk; 1annus 4000annus 20tk; 1annus 2000annus 1tk; 1annus 3000annus 10tk; 1annus 5000annus 10tk; 1annus 1000annus 10tk; 1annus 2000annus 10tk; 1annus 3000annus 20tk; 1annus 2500annus 10tk; 1annus 3000annus 1tk; 1annus 500annus 1tk; 1annus 1000annus 20tk; 1annus 2000annus 20tk; 1annus 2500annus 20tk

Eesti - eesti - Ravimiamet

huvepharma - tiamuliin - lahus joogivees manustamiseks - 101,2mg 1ml 1000ml 1tk; 101,2mg 1ml 5000ml 1tk

Eesti - eesti - Ravimiamet

intervet international b.v. - newcastle'i tõve viirus-/paramüksoviirusvaktsiin - okulonasaalsuspensiooni lüofilisaat - 5000annus 1tk; 1000annus 1tk; 500annus 10tk

Eesti - eesti - Ravimiamet

lohmann animal health gmbh - newcastle'i tõve viirus-/paramüksoviirusvaktsiin - suspensiooni lüofilisaat - 10000annus 1tk; 1000annus 1tk; 10000annus 10tk; 500annus 1tk

Eesti - eesti - Ravimiamet

genera d.d. - newcastle'i tõve viirus-/paramüksoviirusvaktsiin - okulonasaalsuspensiooni lüofilisaat - 2500annus 10tk; 1000annus 10tk